Cargando…
Complete Clinical Response in Stage IVB Endometrioid Endometrial Carcinoma after First-Line Pembrolizumab Therapy: Report of a Case with Isolated Loss of PMS2 Protein
Endometrial cancer is the only gynecological cancer that is rising in incidence and associated mortality worldwide. Although most cases are diagnosed as early stage disease, with chances of cure after primary surgical treatment, those with advanced or metastatic disease have a poor prognosis because...
Autores principales: | Carvalho, Jesus Paula, Del Giglio, Auro, Achatz, Maria Isabel, Carvalho, Filomena Marino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548939/ https://www.ncbi.nlm.nih.gov/pubmed/33082750 http://dx.doi.org/10.1159/000510000 |
Ejemplares similares
-
Complete Pathologic Response to PARP Inhibitor Olaparib in a Patient with Stage IVB Recurrent Endometrioid Endometrial Adenocarcinoma
por: Senguttuvan, Rosemary Noel, et al.
Publicado: (2023) -
Complete resection after pembrolizumab treatment followed by salvage surgery in stage IVB endometrial cancer: A case report
por: Taguchi, Tomomi, et al.
Publicado: (2022) -
L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion
por: de Freitas, Daniela, et al.
Publicado: (2018) -
Pembrolizumab in FIGO IVB Verrucous Carcinoma of the Vulva: A Case Report
por: Wang, Yuhan, et al.
Publicado: (2021) -
Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review
por: Capozzi, Vito Andrea, et al.
Publicado: (2023)